Gulf Breeze

Resilience Network


You are here

Home

Treatments

Vigorous exercise may be OK for people with long COVID-new Swedish study

Mon, 2024-04-08 09:11 — mike kraft
No need to avoid exercise with long-COVID diagnosis, researchers say Recommendations that people with long COVID, or post-COVID condition (PCC), should avoid vigorous exercise are probably too strict, according to a new study published in JAMA Network Open from researchers at the Karolinska Institutet in Sweden. CIDRAP
Country / Region Tags: 
Global
Sweden
General Topic Tags: 
COVID-19
Symptoms
Treatments
Disease
Health
Public Health
Research
Social behavior
Problem, Solution, SitRep, or ?: 
Analysis

Paxlovid does not shorten COVID symptoms among fully vaccinated--study

Fri, 2024-04-05 09:21 — mike kraft
Among fully vaccinated, study shows Paxlovid does not shorten symptoms A new study in the New England Journal of Medicine suggests that, for those fully vaccinated against COVID-19 but having at least one risk factor for severe COVID, the antiviral drug Paxlovid did little to reduce symptom duration, but experts caution the findings might not apply to older patients. CIDRAP

...

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Symptoms
Treatments
Disease
Health
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis

HHS tells hospitals to get patient consent before invasive exams

Tue, 2024-04-02 09:20 — mike kraft
HHS tells hospitals to get patient consent before invasive exams Hospitals must obtain informed consent from patients before allowing physicians to conduct sensitive and invasive examinations, such as pelvic and prostate, particularly if the patients are under a… nweixel The Hill

Hospitals must obtain informed consent from patients before allowing physicians to conduct sensitive and invasive examinations, such as pelvic and prostate, particularly if the patients are under anesthesia, the Department of Health and Human Services (HHS) said Monday. 

Country / Region Tags: 
United States
General Topic Tags: 
Treatments
Government
Health
Hospitals
Medical Personnel
Policy
Communication
Problem, Solution, SitRep, or ?: 
Situation Report

Misinformation issue: Four years after shelter-in place, COVID misinformation continues

Mon, 2024-04-01 10:49 — mike kraft
Four Years After Shelter-in-Place, Covid-19 Misinformation Persists - KFF Health News False claims that covid vaccines cause deaths and other diseases are still prevalent despite multiple studies showing the vaccines are safe and saved lives. khnkit KFF Health News

...

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Pandemics
Politics
Public Attitudes
Public Health
Social behavior
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report

Covid pandemic provided an opportunity to watch the human immune system respond in real time

Fri, 2024-03-29 09:46 — mike kraft
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time Covid wreaked havoc on the world. It also provided an unprecedented look at the human immune system. Helen Branswell STAT

...

The Covid pandemic marked the first time people armed with powerful scientific tools could study how the immune system awakens to and develops defenses against a new threat, in real time, in the global population.

...

 

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Contagion
Symptoms
Treatments
Disease
Disease Prevention
Health
Medical Personnel
Mutations
Pandemics
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis

U.S. FDA settles lawsuit over its criticisms of using ivermectin to counter COVID

Fri, 2024-03-29 09:14 — mike kraft

...

FDA settles lawsuit over ivermectin content that doctors claimed harmed their practice | CNN The US Food and Drug Administration has settled a lawsuit over some of its posts about ivermectin, including what may have been one of its more popular pandemic-era social media campaigns. Jen Christensen CNN

The FDA said in an email to CNN on Wednesday that it “has chosen to resolve this lawsuit rather than continuing to litigate over statements that are between two and nearly four years old.”

Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Government
Health
Policy
Politics
Public Health
Science
Problem, Solution, SitRep, or ?: 
Situation Report

COVID booster cuts severe COVID risk by a third in patients with weak immune systems--study

Thu, 2024-03-28 16:07 — mike kraft
Study: COVID booster cuts severe COVID risk by a third in patients with weak immune systems One dose of the updated, single-strain COVID-19 vaccine introduced last fall is 38% effective against hospitalization in the 7 to 59 days after receipt and 34% effective at 60 to 119 days in adults with weakened immune systems, yet uptake in this group is low, estimates a study published today in Morbidity and Mortality Weekly Report. CIDRAP

 

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Boosters
Treatments
Disease
Disease Prevention
Health
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

U.S. FDA approves COVID preventive Pemgarda for immunocompromised persons

Tue, 2024-03-26 09:08 — mike kraft

 

FDA OKs Invivyd's COVID preventive Pemgarda for emergency use The pre-exposure treatment is indicated for adolescents and adults with moderate-to-severe immunocompromising conditions. CIDRAP

The Food and Drug Administration (FDA) on March 22 granted emergency use authorization (EUA) for Invivyd's monoclonal antibody to prevent COVID-19 in immunocompromised patients, which fills a gap following the withdrawal of Evusheld in January 2023.

Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Treatments
Disease Prevention
Public Health
Research
Problem, Solution, SitRep, or ?: 
Situation Report

Paxlovid outperforms molnupiravir against severe COVID-19 outcomes --study

Mon, 2024-03-25 09:16 — mike kraft

 

New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes A large study yesterday in the International Journal of Infectious Diseases shows that, if prescribed within 5 days of confirmed infection, Paxlovid (nirmatrelvir-ritonavir) is more effective in protecting against all-cause mortality and severe COVID-19 in adults than is molnupiravir, another antiviral drug. CIDRAP

...

Country / Region Tags: 
Asia
China
Global
General Topic Tags: 
COVID-19
Treatments
Data
Disease
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

COVID vaccines cut post infection risk of heart failure and blood clots--study

Thu, 2024-03-21 08:53 — mike kraft

 

Country / Region Tags: 
Global
UK - London
United Kingdom
General Topic Tags: 
COVID-19
Symptoms
Treatments
Data
Disease Prevention
Health
Public Health
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Pages

Subscribe to Treatments
howdy folks